Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)
China · Delayed Price · Currency is CNY 1.540
-0.010 (-0.65%)
Sep 10, 2026, 2:10 PM CST
SHE:000078 Revenue
Shenzhen Neptunus Bioengineering had revenue of 5.35B CNY in the quarter ending June 30, 2026, a decrease of -22.81%. This brings the company's revenue in the last twelve months to 23.66B, down -15.51% year-over-year. In the year 2025, Shenzhen Neptunus Bioengineering had annual revenue of 26.67B, down -12.04%.
Revenue (ttm)
23.66B
Revenue Growth
-15.51%
P/S Ratio
0.17
Revenue / Employee
3.51M
Employees
6,734
Market Cap
4.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.67B | -3.65B | -12.04% |
| Dec 31, 2024 | 30.32B | -6.10B | -16.75% |
| Dec 31, 2023 | 36.42B | -1.42B | -3.74% |
| Jan 1, 2023 | 37.83B | -3.22B | -7.84% |
| Jan 1, 2022 | 41.05B | 1.03B | 2.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.46B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Tibet Weixinkang Medicine | 1.13B |
| Harbin Medisan Pharmaceutical | 805.09M |
| Shandong Wohua Pharmaceutical | 784.94M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Newland Pharmaceutical | 710.55M |
| Shaanxi Kanghui Pharmaceutical | 429.09M |